NCT05675111View on ClinicalTrials.gov

Immune Checkpoint Inhibitors(ICPis)-Induced Endocrine Immune-related Adverse Events (irAEs)

CompletedOBSERVATIONAL
Enrollment

12,408

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

March 31, 2022

Study Completion Date

October 30, 2022

Conditions
Immune Checkpoint InhibitorEndocrine Toxicity
Trial Locations (1)

210029

First Affiliated Hospital, Nanjing Medical University, Nanjing

Sponsors
All Listed Sponsors
lead

Nanjing Medical University

OTHER